-
ISIN | INE221I01017 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Exchange | NSE |
CurrencyCode | INR |
PE Ratio | 1.09 |
---|---|
Dividend Yield | None |
Beta | -0.08 |
Market Cap | 46M |
Celestial Biolabs Limited provides herbal, enzymes, and nutraceutical products in India. Its herbal products include granules to control stress; capsules for diarrhea, dysentery, Ibs and amoebiasis, allergic dermatitis, sinusitis, upper respiratory tract infection, fever, and cerebrovascular disease; tablets for stamina and strength; syrups, such as liver tonics, blood purifier, and digestive tonics, as well as syrups to treat gynecological disorders, cough and allergic disorders, and functional or metabolic efficiency; oils for pain and mobility; and fairness creams, as well as various ayurvedic products. The company also offers various enzyme products for use in detergent, textile, pulp and paper, poultry feed additive, grain-based distillery, molasses based distillery, sugar, and food processing industries. In addition, it provides nutraceuticals for use in GI health, antibacterial/antifungal/antithrombotic/anti-inflammatory, cancer, mental visual function, menopause, heart disease, bone health, cancer, blood sugar, antioxidant, and cardiovascular applications. The company was formerly known as Celestial Technologies Limited and changed its name to Celestial Biolabs Limited in February 2004. Celestial Biolabs Limited was incorporated in 1997 and is based in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CELESTIAL.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025